{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:56:07Z","timestamp":1790276167615,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1007\/s00280-006-0187-8","type":"journal-article","created":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T15:29:07Z","timestamp":1138202947000},"page":"494-503","source":"Crossref","is-referenced-by-count":66,"title":["Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea"],"prefix":"10.1007","volume":"58","author":[{"given":"K.","family":"Takasuna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Onose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kumazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kamataki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"key":"187_CR1","first-page":"5944","volume":"47","author":"T Kunimoto","year":"1987","unstructured":"Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944\u20135947","journal-title":"Cancer Res"},{"key":"187_CR2","first-page":"4187","volume":"51","author":"Y Kawato","year":"1991","unstructured":"Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187\u20134191","journal-title":"Cancer Res"},{"key":"187_CR3","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1200\/JCO.1993.11.11.2194","volume":"11","author":"ML Rothenberg","year":"1993","unstructured":"Rothenberg ML, Kuhn JG, Burris III HA, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, Rock MK, VonHoff DD (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194\u20132204","journal-title":"J Clin Oncol"},{"key":"187_CR4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.1993.11.5.909","volume":"11","author":"Y Shimada","year":"1993","unstructured":"Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909\u2013913","journal-title":"J Clin Oncol"},{"key":"187_CR5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.1992.10.1.16","volume":"10","author":"M Fukuoka","year":"1992","unstructured":"Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16\u201320","journal-title":"J Clin Oncol"},{"key":"187_CR6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMoa003034","volume":"346","author":"K Noda","year":"2002","unstructured":"Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokohama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N (2002) Irinnoteacn plus cisplatin compared with etoposide plus cisplatin for extensive small-cell-lung cancer. N Engl J Med 346:85\u201391","journal-title":"N Engl J Med"},{"key":"187_CR7","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.1990.8.11.1907","volume":"8","author":"R Ohno","year":"1990","unstructured":"Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaku S, Ota K (1990) An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907\u20131912","journal-title":"J Clin Oncol"},{"key":"187_CR8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1056\/NEJMoa010957","volume":"345","author":"DJ Sargent","year":"2001","unstructured":"Sargent DJ, Niedzwiechi D, O\u2019Connell MJ, Schilsky RL (2001) Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:144\u2013145","journal-title":"N Engl J Med"},{"issue":"8 Suppl 6","key":"187_CR9","first-page":"72","volume":"12","author":"JR Hecht","year":"1998","unstructured":"Hecht JR (1998) Gastrointestinal toxicity of irinotecan. Oncology 12(8 Suppl 6):72\u201378","journal-title":"Oncology"},{"key":"187_CR10","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1998.16.8.2745","volume":"16","author":"F Saliba","year":"1998","unstructured":"Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, Mignard D, Cvitkovic E (1998) Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 16:2745\u20132751","journal-title":"J Clin Oncol"},{"key":"187_CR11","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/jnci\/84.12.972","volume":"84","author":"Y Ohe","year":"1993","unstructured":"Ohe Y, Sakai Y, Shinkai T, Eguchi K, Tamura T, Kojima A, Kunikane H, Okamoto H, Karato A, Ohmatsu H, Kanzawa F, Saijo N (1993) Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84:972\u2013974","journal-title":"J Natl Cancer Inst"},{"key":"187_CR12","first-page":"141","volume":"12","author":"S Kudoh","year":"1993","unstructured":"Kudoh S, Fukuoka M, Masuda N, Kusunoki Y, Matsui K, Negoro S, Takifuji N, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yana H, Takada M (1993) Relationship between CPT-11 pharmacokinetics and diarrhea in the combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP). Proc Am Soc Clin Oncol 12:141","journal-title":"Proc Am Soc Clin Oncol"},{"key":"187_CR13","first-page":"3723","volume":"54","author":"E Gupta","year":"1994","unstructured":"Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54:3723\u20133725","journal-title":"Cancer Res"},{"key":"187_CR14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/oxfordjournals.annonc.a059108","volume":"6","author":"G Catimel","year":"1995","unstructured":"Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C (1995) Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 6:133\u2013140","journal-title":"Ann Oncol"},{"key":"187_CR15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/oxfordjournals.annonc.a059109","volume":"6","author":"GG Chabot","year":"1995","unstructured":"Chabot GG, Abigerges D, Catimel G, Culine S, DeForni M, Extra JM (1995) Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141\u2013151","journal-title":"Ann Oncol"},{"key":"187_CR16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1067\/mcp.2002.126741","volume":"72","author":"R Xie","year":"2002","unstructured":"Xie R, Mathijssen RHJ, Sparreboom A, Verweij J, Karlsson MO (2002) Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 72:265\u2013275","journal-title":"Clin Pharmacol Ther"},{"key":"187_CR17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/bjc.1993.427","volume":"68","author":"N Masuda","year":"1993","unstructured":"Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Takifuji N, Nakazawa K, Tamanoi M, Nitta T, Hirashima T, Negoro S, Takada M (1993) Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68:777\u2013782","journal-title":"Br J Cancer"},{"key":"187_CR18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/jnci\/86.6.446","volume":"86","author":"D Abigerges","year":"1994","unstructured":"Abigerges D, Armand JP, Chabot GG, DaCosta L, Fadel E, Cote C, H\u00e9rait P, Gandia D (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446\u2013449","journal-title":"J Natl Cancer Inst"},{"key":"187_CR19","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0006-2952(96)00457-1","volume":"52","author":"LP Rivory","year":"1996","unstructured":"Rivory LP, Bowels MR, Robert J, Pond SM (1996) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52:1103\u20131111","journal-title":"Biochem Pharmacol"},{"key":"187_CR20","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1007\/s002800050595","volume":"39","author":"E Gupta","year":"1997","unstructured":"Gupta E, Wang X, Ramirez J (1997) Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital. Cancer Chemother Pharmacol 39:4440\u20134444","journal-title":"Cancer Chemother Pharmacol"},{"key":"187_CR21","first-page":"1309","volume":"56","author":"E Gupta","year":"1996","unstructured":"Gupta E, Safa AR, Wang X (1996) Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin. Cancer Res 56:1309\u20131314","journal-title":"Cancer Res"},{"key":"187_CR22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2133\/dmpk.17.23","volume":"17","author":"M Horikawa","year":"2002","unstructured":"Horikawa M, Kato Y, Tyson CA, Sugiyama Y (2002) The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet 17:23\u201333","journal-title":"Drug Metab Pharmacokinet"},{"key":"187_CR23","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1023\/A:1023847521767","volume":"20","author":"K Arimori","year":"2003","unstructured":"Arimori K, Kuroki N, Hidaka M, Iwakiri T, Yamasaki K, Okumura M, Ono H, Takamura N, Kikuchi M, Nakano M (2003) Effect of p-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats. Pharm Res 20:910\u2013917","journal-title":"Pharm Res"},{"key":"187_CR24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1211\/0022357023420","volume":"56","author":"T Itoh","year":"2004","unstructured":"Itoh T, Itagaki S, Sasaki K, Hirano T, Takemoto I, Iseki K (2004) Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats. J Pharm Pharmacol 56:809\u2013812","journal-title":"J Pharm Pharmacol"},{"key":"187_CR25","first-page":"1721","volume":"50","author":"N Kaneda","year":"1990","unstructured":"Kaneda N, Yokokura T (1990) Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721\u2013172","journal-title":"Cancer Res"},{"key":"187_CR26","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3109\/00498259109039556","volume":"21","author":"R Atsumi","year":"1991","unstructured":"Atsumi R, Suzuki W, Hakusui H (1991) Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21:1159\u20131169","journal-title":"Xenobiotica"},{"issue":"8 Suppl 6","key":"187_CR27","first-page":"39","volume":"12","author":"JG Kuhn","year":"1998","unstructured":"Kuhn JG (1998) Pharmacology of irinotecan. Oncology 12(8 Suppl 6):39\u201342","journal-title":"Oncology"},{"key":"187_CR28","first-page":"3752","volume":"56","author":"K Takasuna","year":"1996","unstructured":"Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1996) Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 56:3752\u20133757","journal-title":"Cancer Res"},{"key":"187_CR29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s002800050818","volume":"42","author":"K Takasuna","year":"1998","unstructured":"Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T (1998) Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42:280\u2013286","journal-title":"Cancer Chemother Pharmacol"},{"key":"187_CR30","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1349-7006.1995.tb03010.x","volume":"86","author":"K Takasuna","year":"1995","unstructured":"Takasuna K, Kasai Y, Kitano Y, Mori K, Kobayashi R, Hagiwara T, Kakihata K, Hirohashi M, Nomura M, Nagai E, Kamataki T (1995) Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn J Cancer Res 86:978\u2013984","journal-title":"Jpn J Cancer Res"},{"key":"187_CR31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00280-003-0585-0","volume":"51","author":"K Mori","year":"2003","unstructured":"Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K (2003) Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 51:403\u2013406","journal-title":"Cancer Chemother Pharmacol"},{"key":"187_CR32","first-page":"1136","volume":"7","author":"DF Kehrer","year":"2001","unstructured":"Kehrer DF, Sparreboom A, Verweij J, DeBruijn P, Nierop CA, Van de Schraaf J, Ruijgrok EJ, DeJonge MJ (2001) Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 7:1136\u20131141","journal-title":"Clin Cancer Res"},{"key":"187_CR33","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/annonc\/mdg193","volume":"14","author":"A Alimonti","year":"2003","unstructured":"Alimonti A, Satta F, Pavese I, Burattini E, Zoffoli V, Vecchione A (2003) Prevention of irinotecan plus 5-fluorouracil\/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol 14:805\u2013806","journal-title":"Ann Oncol"},{"key":"187_CR34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1179>3.0.CO;2-3","volume":"92","author":"Y Takeda","year":"2001","unstructured":"Takeda Y, Kobayashi K, Akiyama Y, Soma T, Handa S, Kudoh S, Kudoh K (2001) Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients. Int J Cancer 92:269\u2013275","journal-title":"Int J Cancer"},{"key":"187_CR35","first-page":"179","volume":"62","author":"T Ikegami","year":"2002","unstructured":"Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S, Matsuzaki Y, Bouscarel B (2002) Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 62:179\u2013187","journal-title":"Cancer Res"},{"key":"187_CR36","unstructured":"Michael M, Brittain M, Nagai J, Feld R, Hedley D, Oza A, Siu M, Moore J (2001) A phase II study of activated charcoal to prevent irinotecan (CPT-11) induced diarrhea (abstract). Proc Am Soc Clin Oncol 1615"},{"key":"187_CR37","first-page":"581","volume":"12","author":"Y Maeda","year":"2004","unstructured":"Maeda Y, Ohune T, Nakamura M, Yamasaki M, Kiribayashi Y, Murakami T (2004) Prevention of irinotecan-induced diarrhoea by oral carbonaceous adsorbent (KremezinTM) in cancer patients. Oncol Rep 12:581\u2013585","journal-title":"Oncol Rep"},{"key":"187_CR38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1254\/fpj.105.447","volume":"105","author":"K Takasuna","year":"1995","unstructured":"Takasuna K, KasaiY, Kitano Y, Mori K, Kakihata K, Hirohashi M, Nomura M (1995) Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats (in Japanese). Folia Pharmacol Jpn 105:447\u2013460","journal-title":"Folia Pharmacol Jpn"},{"key":"187_CR39","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1248\/cpb.35.705","volume":"35","author":"T Akao","year":"1987","unstructured":"Akao T, Akao T, Kobayashi K (1987) Glycyrrhizin \u03b2-d-glucuronidase of Eubacterium sp from human intestinal flora. Chem Pharm Bull 35:705\u2013710","journal-title":"Chem Pharm Bull"},{"key":"187_CR40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.1993.11.1.196","volume":"11","author":"D Gandia","year":"1993","unstructured":"Gandia D, Abigerges D, Armand JP (1993) CPT-11-induced cholinergic effects in cancer patients (letter). J Clin Oncol 11:196\u2013197","journal-title":"J Clin Oncol"},{"key":"187_CR41","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.2042-7158.1993.tb05573.x","volume":"45","author":"Y Kawato","year":"1993","unstructured":"Kawato Y, Sekiguchi M, Akahane K, Tsutomi Y, Hirota Y, Kuga H, Suzuki W, Hakusui H, Sato K (1993) Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. J Pharm Pharmacol 45:444\u2013448","journal-title":"J Pharm Pharmacol"},{"key":"187_CR42","first-page":"1458","volume":"59","author":"CL Morton","year":"1999","unstructured":"Morton CL, Wadkins RM, Danks MK, Potter PM (1999) The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res 59:1458\u20131463","journal-title":"Cancer Res"},{"key":"187_CR43","first-page":"233","volume":"295","author":"T Suzuki","year":"2000","unstructured":"Suzuki T, Sakai H, Ikari A, Takeguchi N (2000) Inhibition of thromboxane A(2)-induced Cl(\u2212) secretion by antidiarrhea drug loperamide in isolated rat colon. J Pharmacol Exp Ther 295:233\u2013238","journal-title":"J Pharmacol Exp Ther"},{"key":"187_CR44","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s005200000220","volume":"9","author":"V Barbounis","year":"2001","unstructured":"Barbounis V, Koumakis G, Vassilomanolakis M, Demiri M, Efremidis AP (2001) Control of irinotecan-induced diarrhea by octreotide after loperamide failure. Support Care Cancer 9:258\u2013260","journal-title":"Support Care Cancer"},{"key":"187_CR45","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00432-004-0557-8","volume":"130","author":"M Fittkau","year":"2004","unstructured":"Fittkau M, Vogit W, Holzhausen HJ, Schmoll HJ (2004) Saccharic acid 1,4-lactone protects against CPT-11-induced mucosa damage in rats. J Cancer Res Clin Oncol 130:388\u2013394","journal-title":"J Cancer Res Clin Oncol"},{"key":"187_CR46","first-page":"1336","volume":"65","author":"RM Wadkins","year":"2004","unstructured":"Wadkins RM, Hyatt JL, Yoon KJP, Morton CL, Lee RE, Damodaran K, Beroza P, Danks MK, Potter PM (2004) Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure\u2013activity relationship analysis, and biological activity. J Pharmacol Exp Ther 65:1336\u20131343","journal-title":"J Pharmacol Exp Ther"},{"key":"187_CR47","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/(SICI)1097-0215(19991112)83:4<491::AID-IJC10>3.0.CO;2-M","volume":"83","author":"K Kobayashi","year":"1999","unstructured":"Kobayashi K, Bouscarel B, Matsuzaki Y, Ceryak S, Kudoh S, Fromm H (1999) pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. Int J Cancer 83:491\u2013496","journal-title":"Int J Cancer"},{"key":"187_CR48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/00498259309059356","volume":"21","author":"M Narita","year":"1993","unstructured":"Narita M, Nagai E, Hagiwara H, Aburada M, Yokoi T, Kamataki T (1993) Inhibition of \u03b2-glucuronidase by natural glucuronides of Kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica 21:5\u201310","journal-title":"Xenobiotica"},{"key":"187_CR49","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1254\/jjp.75.407","volume":"75","author":"Y Kase","year":"1997","unstructured":"Kase Y, Hayakawa T, Aburada M, Komatsu Y, Kamataki T (1997) Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat. Jpn J Pharmacol 75:407\u2013413","journal-title":"Jpn J Pharmacol"},{"key":"187_CR50","first-page":"745","volume":"10","author":"B Chowbay","year":"2003","unstructured":"Chowbay B, Sharma A, Zhou QU, Cheung YB, Lee ED (2003) The modulation of irinotecan-induced diarrhea and pharmacokinetics by three different classes of pharmacologic agents. Oncol Rep 10:745\u2013775","journal-title":"Oncol Rep"},{"key":"187_CR51","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.1995.13.8.2144","volume":"13","author":"E Goncalves","year":"1995","unstructured":"Goncalves E, DeCosta L, Abigerges D, Armand JP (1995) A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11. J Clin Oncol 13:2144\u20132146","journal-title":"J Clin Oncol"},{"key":"187_CR52","first-page":"5778","volume":"15","author":"OC Trifan","year":"2002","unstructured":"Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, Davis TW, Masferrer JL (2002) Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 15:5778\u20135784","journal-title":"Cancer Res"},{"key":"187_CR53","first-page":"3270","volume":"58","author":"S Cao","year":"1998","unstructured":"Cao S, Black JD, Troutt AB, Rustum YM (1998) Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res 58:3270\u20133274","journal-title":"Cancer Res"},{"key":"187_CR54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1023\/A:1010678214152","volume":"19","author":"B Pro","year":"2001","unstructured":"Pro B, Lozano R, Ajani JA (2001) Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. Invest New Drugs 19:341\u2013343","journal-title":"Invest New Drugs"},{"key":"187_CR55","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1008372228462","volume":"12","author":"J Zidan","year":"2001","unstructured":"Zidan J, Haim N, Beny A, Stein M, Gez E, Kuten A (2001) Octreotide in the treatment of severe chemotherapy-induced diarrhea. Ann Oncol 12:227\u2013229","journal-title":"Ann Oncol"},{"key":"187_CR56","first-page":"2053","volume":"4","author":"H Shinohara","year":"1998","unstructured":"Shinohara H, Killion JJ, Kuniyasu H, Kumar R, Fidler IJ (1998) Prevention of intestinal toxic effect and intensification of irinotecan\u2019s therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT-3002. Clin Cancer Res 4:2053\u20132063","journal-title":"Clin Cancer Res"},{"key":"187_CR57","first-page":"2148","volume":"5","author":"H Shinohara","year":"1999","unstructured":"Shinohara H, Killion JJ, Bucana CD, Yano S, Fidler IJ (1999) Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium. Clin Cancer Res 5:2148\u20132156","journal-title":"Clin Cancer Res"},{"key":"187_CR58","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1158\/1078-0432.CCR-03-0496","volume":"Res15","author":"J Zhao","year":"2004","unstructured":"Zhao J, Huang L, Belmar N, Buelow R, Fong T (2004) Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res15:2851\u20132859","journal-title":"Clin Cancer"},{"key":"187_CR59","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/cncr.10432","volume":"94","author":"ML Delioukina","year":"2002","unstructured":"Delioukina ML, Prager D, Parson M, Hecht JR, Rosen P, Rosen LS (2002) Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. Cancer 94:2174\u20132179","journal-title":"Cancer"},{"key":"187_CR60","first-page":"3727","volume":"22","author":"J Duffour","year":"2002","unstructured":"Duffour J, Gourgou S, Seitz JF, Senesse P, Boutet O, Castera D, Kramar A, Ychou M (2002) Efficacy of prophyractic anti-diarrhoeal treatment in patients receiving Campto for advanced colorectal cancer. Anticancer Res 22:3727\u20133732","journal-title":"Anticancer Res"},{"key":"187_CR61","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0140-6736(00)02586-1","volume":"356","author":"R Govindarajan","year":"2000","unstructured":"Govindarajan R, Heaton KM, Broadwater R, Zeitlin A, Lang NP, Hauer-Jensen M (2000) Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 356:566\u2013567","journal-title":"Lancet"},{"key":"187_CR62","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00000421-200206000-00025","volume":"25","author":"NS Tchekmedyian","year":"2002","unstructured":"Tchekmedyian NS (2002) Thalidomide and irinotecan-associated diarrhea. Am J Clin Oncol 25:324","journal-title":"Am J Clin Oncol"},{"key":"187_CR63","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1200\/JCO.2000.18.2.450","volume":"18","author":"D Savarese","year":"2000","unstructured":"Savarese D, Al-Zoubi A, Boucher J (2000) Glutamine for irinotecan diarrhea. J Clin Oncol 18:450\u2013451","journal-title":"J Clin Oncol"},{"key":"187_CR64","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1023\/A:1008390308416","volume":"10","author":"BHM Lenfers","year":"1999","unstructured":"Lenfers BHM, Loeffler TM, Droege CM, Hausamen TU (1999) Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. Ann Oncol 10:1251\u20131253","journal-title":"Ann Oncol"},{"key":"187_CR65","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/sj.bjc.6690713","volume":"81","author":"WE Hardman","year":"1999","unstructured":"Hardman WE, Moyer MP, Cameron IL (1999) Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects. Br J Cancer 81:440\u2013448","journal-title":"Br J Cancer"},{"key":"187_CR66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s002800000151","volume":"46","author":"A Kurita","year":"2000","unstructured":"Kurita A, Kado S, Kaneda N, Onoue M, Hashimoto S, Yokokura T (2000) Modified irinotecan hydrochloride (CPT-11) administration schedule improves induction of delayed-onset diarrhea in rats. Cancer Chemother Pharmacol 46:211\u2013220","journal-title":"Cancer Chemother Pharmacol"},{"key":"187_CR67","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0361-090X(02)00060-0","volume":"26","author":"H Fujii","year":"2002","unstructured":"Fujii H, Koshiyama M, Konishi M, Yoshida M, Tauchi K (2002) Intermittent, repetitive administrations of irinotecan (CPT-11) reduces its side-effects. Cancer Detect Prev 26:210\u2013212","journal-title":"Cancer Detect Prev"},{"key":"187_CR68","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00280-003-0682-0","volume":"52","author":"A Kurita","year":"2003","unstructured":"Kurita A, Kado S, Kaneda N, Onoue M, Hashimoto S, Yokokura T (2003) Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion. Cancer Chemother Pharmacol 52:349\u2013360","journal-title":"Cancer Chemother Pharmacol"},{"key":"187_CR69","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y (2000) Polymorphism of UDP-glucuronosyltranferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921\u20136926","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0187-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-006-0187-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0187-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T06:15:34Z","timestamp":1586672134000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-006-0187-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,25]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["187"],"URL":"https:\/\/doi.org\/10.1007\/s00280-006-0187-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,25]]}}}